港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

海西新藥

109.500

-0.500-0.45%

成交量：9.31萬

成交額：1,026.13萬

市值：86.18億

市盈率：- -

高：113.700

開：112.200

低：106.800

收：110.000

52周最高：117.800

52周最低：97.500

股本：7,870.73萬

香港流通股本：7,870.73萬

量比：0.12

換手率：0.12%

股息：- -

股息率：- -

淨資產收益率：28.75%

總資產收益率：12.62%

市淨率：14.58

市盈率(LYR):- -

市銷率: 16.91

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

海西新藥10月24日主力淨流出6.9萬元散户資金買入

港股異動 | 海西新藥(02637)一度漲超12% 較招股價漲超三成仿製藥、創新藥雙線佈局

又一藥企登陸港股！醫藥行業赴港IPO熱潮持續升温

異動解讀 | 海西新藥盤中大跌5.04%，高度依賴集採產品引發擔憂

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/02637"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新藥","latestPrice":109.5,"timestamp":1761293295066,"preClose":110,"halted":0,"volume":93050,"delay":0,"floatShares":78707270,"shares":78707270,"eps":0,"marketStatus":"未開盤","change":-0.5,"latestTime":"10-24 16:08:15","open":112.2,"high":113.7,"low":106.8,"amount":10261285,"amplitude":0.062727,"askPrice":109.6,"askSize":50,"bidPrice":108.2,"bidSize":350,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1761528600000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":110,"openAndCloseTimeList":[[1761269400000,1761278400000],[1761282000000,1761292800000]],"volumeRatio":0.11675580719522825,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"12.62%","roe":"28.75%","lyrEps":0,"volumeRatio":0.11675580719522825,"shares":78707270,"dividePrice":0,"high":113.7,"amplitude":0.062727,"preClose":110,"low":106.8,"week52Low":97.5,"pbRate":"14.58","psRate":"16.91","week52High":117.8,"institutionHeld":0,"latestPrice":109.5,"committee":0.75,"eps":0,"divideRate":0,"volume":93050,"delay":0,"ttmEps":0,"open":112.2,"prevYearClose":86.4,"prevWeekClose":86.4,"prevMonthClose":86.4,"prevQuarterClose":86.4,"fiveDayClose":86.4,"twentyDayClose":86.4,"sixtyDayClose":86.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2025-10-24","current":58.044665,"percent":0.8,"low":41.43616,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"high":58.309709,"avg":53.51076,"sd":5.672952,"marketCap":8618446065},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065}],"updateTime":1761476014565},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577593583","title":"海西新藥10月24日主力淨流出6.9萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2577593583","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577593583?lang=zh_tw&edition=fundamental","pubTime":"2025-10-24 16:15","pubTimestamp":1761293721,"startTime":"0","endTime":"0","summary":"10月24日, 海西新药股价跌0.45%，报收109.50元，成交金额1026.1万元，换手率0.12%，振幅6.27%，量比0.00。海西新药今日主力资金净流出6.9万元，上一交易日主力净流入273.4万元。该股近5个交易日上涨26.74%，主力资金累计净流入53.9万元；近20日主力资金累计净流入53.9万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024161632a4723cf1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024161632a4723cf1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637"],"gpt_icon":0},{"id":"2577332211","title":"港股異動 | 海西新藥(02637)一度漲超12% 較招股價漲超三成 仿製藥、創新藥雙線佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2577332211","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577332211?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 14:09","pubTimestamp":1761199757,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药(02637)一度涨超12% ，高见114.9港元，较招股价86.4港元涨超30%。截至发稿，涨9.2%，报111.6港元，成交额2093.12万港元。据悉，海西新药是一家处于商业化阶段的制药公司，集研发、生产及销售能力于一体，具备在研创新药的管线。截至招股书披露日，海西新药获批上市的仿制药产品有15款，产品组合涵盖了多个治疗领域，包括消化系统、心血管系统、内分泌系统、神经系统等。公司亦已建立四款在研创新药的产品管线，涵盖癌症、眼科及呼吸系统疾病。海西新药此前在招股书中称，未来计划积极探索与跨国公司(MNC)合作的机会，以扩大公司的国际临床研究及商业化能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","02637","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2577844491","title":"又一藥企登陸港股！醫藥行業赴港IPO熱潮持續升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2577844491","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577844491?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 15:43","pubTimestamp":1761032617,"startTime":"0","endTime":"0","summary":"如10月20日，海西新药正式登陆港股市场，本次募资总额达到约9.94亿港元。根据梳理，除了海西新药外，今年9月以来，至少还有9家A股药企宣布赴港IPO进展。如2025年9月30日一天，四家A股药企密集披露赴港IPO进展。业内表示，随着更多药企进入上市通道，港股正逐步巩固 “全球生物医药创新资本引擎” 的地位，而这场 IPO 热潮，或许只是中国医药产业国际化升级的序幕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021155037a46bda6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021155037a46bda6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637"],"gpt_icon":0},{"id":"1174412031","title":"異動解讀 | 海西新藥盤中大跌5.04%，高度依賴集採產品引發擔憂","url":"https://stock-news.laohu8.com/highlight/detail?id=1174412031","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174412031?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 09:52","pubTimestamp":1761011555,"startTime":"0","endTime":"0","summary":"10月21日（周二）上午，港股上市新秀海西新药盘中大跌5.04%，引发市场广泛关注。该公司刚于10月20日在港交所挂牌上市，首日表现亮眼，收盘上涨20.60%。投资者需密切关注海西新药未来的业务转型进展和创新药管线的研发进度，以评估公司的长期发展前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4f283e08a8c52a60fffa4beefbde09d3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"gpt_icon":1}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/02637\",params:#limit:6,delay:false,,,undefined,":[]}}